Actinium Pharmaceuticals, Inc. (Delaware) (ATNM): Price and Financial Metrics


Actinium Pharmaceuticals, Inc. (Delaware) (ATNM): $5.23

0.13 (+2.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATNM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 450

in industry

ATNM POWR Grades


  • Sentiment is the dimension where ATNM ranks best; there it ranks ahead of 73.88% of US stocks.
  • ATNM's strongest trending metric is Growth; it's been moving down over the last 170 days.
  • ATNM's current lowest rank is in the Momentum metric (where it is better than 4.02% of US stocks).

ATNM Stock Summary

  • For ATNM, its debt to operating expenses ratio is greater than that reported by only 6.61% of US equities we're observing.
  • ATNM's price/sales ratio is 102.78; that's higher than the P/S ratio of 97.63% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.06 for Actinium Pharmaceuticals Inc; that's greater than it is for only 6.35% of US stocks.
  • Stocks that are quantitatively similar to ATNM, based on their financial statements, market capitalization, and price volatility, are GNCA, ZSAN, AYLA, STTK, and VBLT.
  • ATNM's SEC filings can be seen here. And to visit Actinium Pharmaceuticals Inc's official web site, go to www.actiniumpharma.com.

ATNM Valuation Summary

  • ATNM's price/sales ratio is 146.1; this is 3744.74% higher than that of the median Healthcare stock.
  • Over the past 106 months, ATNM's price/earnings ratio has gone down 2.
  • Over the past 106 months, ATNM's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ATNM.

Stock Date P/S P/B P/E EV/EBIT
ATNM 2021-08-31 146.1 1.6 -5.8 -2.2
ATNM 2021-08-30 144.1 1.6 -5.7 -2.1
ATNM 2021-08-27 145.6 1.6 -5.8 -2.1
ATNM 2021-08-26 145.8 1.6 -5.8 -2.1
ATNM 2021-08-25 147.0 1.6 -5.9 -2.2
ATNM 2021-08-24 148.2 1.6 -5.9 -2.2

ATNM Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -0.87%.
  • Its 2 year net income to common stockholders growth rate is now at 11.89%.
  • Its 3 year net income to common stockholders growth rate is now at -2.9%.
Over the past 49 months, ATNM's revenue has gone up $1,121,000.

The table below shows ATNM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 1.121 -22.072 -23.144
2021-06-30 0.888 -21.478 -22.261
2021-03-31 0.622 -21.405 -21.866
2020-12-31 0 -21.617 -22.216
2020-09-30 0 -20.36944 -20.43843
2020-06-30 0 -20.97396 -21.49776

ATNM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATNM has a Quality Grade of F, ranking ahead of 4.49% of graded US stocks.
  • ATNM's asset turnover comes in at 0.013 -- ranking 384th of 681 Pharmaceutical Products stocks.
  • EIGR, MNOV, and ATRA are the stocks whose asset turnover ratios are most correlated with ATNM.

The table below shows ATNM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.013 1 14.970
2021-03-31 0.010 1 14.068
2020-12-31 0.000 NA 13.639
2020-09-30 0.000 NA 11.983
2020-06-30 0.000 NA 11.318
2020-03-31 0.000 NA 10.911

ATNM Stock Price Chart Interactive Chart >

Price chart for ATNM

ATNM Price/Volume Stats

Current price $5.23 52-week high $10.30
Prev. close $5.10 52-week low $4.91
Day low $4.95 Volume 70,800
Day high $5.31 Avg. volume 107,505
50-day MA $6.42 Dividend yield N/A
200-day MA $7.24 Market Cap 115.22M

Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) Company Bio


Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company’s targeted radio immunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213, and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The company was founded in 2000 and is based in New York City, New York.


ATNM Latest News Stream


Event/Time News Detail
Loading, please wait...

ATNM Latest Social Stream


Loading social stream, please wait...

View Full ATNM Social Stream

Latest ATNM News From Around the Web

Below are the latest news stories about Actinium Pharmaceuticals Inc that investors may wish to consider to help them evaluate ATNM as an investment opportunity.

H.C. Wainwright Thinks Actinium Pharmaceuticals’ Stock is Going to Recover

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) on January 5 and set a price target of $45.00. The company's shares closed last Tuesday at $6.00, close to its 52-week low of $5.70. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -11.3% and a 25.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics. Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $28.94.

Catie Powers on TipRanks | January 12, 2022

Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPα Immunotherapy

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs and EpicentRx, Inc. ("EpicentRx"), a San Diego-based clinical cancer immunotherapy company today announced that they have entered into a research collaboration to study Actinium's Actimab-A targeted radiotherapy in combination with RRx-001, EpicentRx's novel small molecule immunotherapy targeting the CD47-SIRPα axis. Under this s

Yahoo | January 5, 2022

Alliance Global Partners Thinks Actinium Pharmaceuticals’ Stock is Going to Recover

In a report released today, Matthew Cross from Alliance Global Partners maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $20.00. The company's shares closed last Tuesday at $6.38, close to its 52-week low of $5.70. According to TipRanks.com, Cross is a 3-star analyst with an average return of 6.8% and a 35.4% success rate. Cross covers the Healthcare sector, focusing on stocks such as Syros Pharmaceuticals, Aptose Biosciences, and Gamida Cell. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $28.15 average price target, representing a 309.2% upside.

Christine Brown on TipRanks | December 14, 2021

Actinium Reports Positive Findings From Phase 1 Study Of Actimab-A

WASHINGTON (dpa-AFX) - Actinium Pharmaceuticals, Inc. (ATNM) reported updated data from the recently complete Actimab-A and CLAG-M phase 1 combination trial for patients with relapsed or refractor

FinanzNachrichten | December 14, 2021

Actinium Reports Positive Findings From Phase 1 Study Of Actimab-A - Quick Facts

(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM) reported updated data from the recently complete Actimab-A and CLAG-M phase 1 combination trial for patients with relapsed or refractory AML. Key findings from the study include: complete remissions in all dose cohorts; 72% MRD negativity rate; and 80% overall response rate in patients receiving…

Business Insider Markets | December 14, 2021

Read More 'ATNM' Stories Here

ATNM Price Returns

1-mo -14.12%
3-mo -33.38%
6-mo -24.31%
1-year -33.63%
3-year -68.87%
5-year -82.91%
YTD -12.98%
2021 -22.95%
2020 19.43%
2019 -44.18%
2018 -40.91%
2017 -24.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6787 seconds.